Remission induction in chronic granulocytic leukaemia using intermittent high-dose busulphan.
In a series of 19 patients, the pre-blastic phase of chronic granulocytic leukaemia was controlled with busulphan given as single doses of 50-100 mg at 2-weekly intervals. Although there was no significant increase in the incidence of Ph1-negative cells in the bone marrow, remissions of a better haematological quality were attained more rapidly than with conventional therapy.
D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced
D002066:Busulfan